Claims for Patent: 9,271,931

Summary for Patent: 9,271,931

Title:	Compositions for delivery of drug combinations
Abstract:	Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
Inventor(s):	Tardi; Paul (Surrey, CA), Harasym; Troy (North Vancouver, CA), Webb; Murray (North Vancouver, CA), Shew; Clifford (Vancouver, CA), Janoff; Andrew (Yardley, PA), Bally; Marcel (Bowen Island, CA)
Assignee:	CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:	10/553,373
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,271,931
Patent Claims:	1. A pharmaceutical composition for parenteral administration, comprising particulate delivery vehicles having associated therewith at least a first antineoplastic agent and a second antineoplastic agent, wherein said first and second agents are in a mole ratio which exhibits a non-antagonistic cytotoxic or cytostatic effect in an in vitro assay, over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8; and wherein said first and second agents are associated with the delivery vehicles to maintain said non-antagonistic ratio in the blood for at least one hour after administration, wherein said delivery vehicles comprise liposomes, and/or lipid micelles, and/or block copolymer micelles, and/or polymer microparticles, and/or polymer nanoparticles, and/or polymer lipid hybrid systems, and/or derivatized single chain polymers. 2. The composition of claim 1 wherein said delivery vehicles are 4 to 6,000 nm in diameter. 3. The composition of claim 1 wherein said delivery vehicles have a mean diameter of between 4.5 and 500 nm. 4. The composition of claim 3 wherein said vehicles have a mean diameter of less than 250 nm. 5. The composition of claim 1 wherein said delivery vehicles are from 4 .mu.m to 50 .mu.m in diameter. 6. The composition of claim 1 wherein said delivery vehicles comprise liposomes. 7. The composition of claim 1 wherein said first and second agents are co-encapsulated. 8. The composition of claim 1 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR, or wherein the first agent is idarubicin and the second agent is AraC or FUDR, or wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or wherein the first agent is doxorubicin and the second agent is vinorelbine, or wherein the first agent is carboplatin and the second agent is vinorelbine, or wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine. 9. The composition of claim 8 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR or wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR. 10. A method to prepare a composition of claim 1, which method comprises stably associating with said particulate delivery vehicles a mole ratio of agents that has been determined to exhibit a non-antagonistic cytotoxic or cytostatic effect in an in vitro assay over at least 20% of the concentration range over which the fraction of cells affected is 0.2-0.8; wherein said stable association is such that said ratio is maintained in the blood for at least one hour after administration. 11. The method of claim 10, wherein said ratio has been determined in an assay that employs testing at least one ratio of said agents at a multiplicity of concentrations and applying an algorithm to calculate a synergistic, additive, or antagonistic effect for said ratio over a range of concentrations. 12. The method of claim 11 which employs testing a multiplicity of ratios, and wherein said algorithm is the Chou-Talalay median effect method. 13. The method of claim 10 wherein the delivery vehicles are liposomes. 14. The method of claim 13 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR, or wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR, or wherein the first agent is idarubicin and the second agent is AraC or FUDR, or wherein the first agent is oxaliplatin and the second agent is 5-FU or FUDR, or wherein the first agent is irinotecan and the second agent is cisplatin (or carboplatin), or wherein the first agent is gemcitabine and the second agent is cisplatin (or carboplatin), or wherein the first agent is methotrexate and the second agent is 5-FU or FUDR, or wherein the first agent is paclitaxel and the second agent is cisplatin (or carboplatin), or wherein the first agent is etoposide and the second agent is cisplatin (or carboplatin), or wherein the first agent is docetaxel or paclitaxel and the second agent is doxorubicin, or wherein the first agent is doxorubicin and the second agent is vinorelbine, or wherein the first agent is carboplatin and the second agent is vinorelbine, or wherein the first agent is 5-FU or FUDR and the second agent is gemcitabine. 15. The method of claim 14 wherein the first agent is irinotecan and the second agent is 5-FU or FUDR or wherein the first agent is cisplatin (or carboplatin) and the second agent is 5-FU or FUDR.